A5016987068- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Ovarian cancer diagnosis and treatment
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Breast Lesions and Carcinomas
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Lung Cancer Treatments and Mutations
- Caveolin-1 and cellular processes
- Peptidase Inhibition and Analysis
- Economic and Financial Impacts of Cancer
- Chronic Lymphocytic Leukemia Research
- Breast Implant and Reconstruction
- Neutropenia and Cancer Infections
- Cancer, Lipids, and Metabolism
- Intraperitoneal and Appendiceal Malignancies
- Bone health and treatments
- PI3K/AKT/mTOR signaling in cancer
- Cancer Risks and Factors
- Colorectal Cancer Treatments and Studies
Kliniken Essen-Mitte
2012-2025
Cancer Clinic
2025
NSABP Foundation
2025
National Cancer Institute
2019-2025
National Center for Tumor Diseases
2013-2025
Helios Hospital Berlin-Buch
2003-2025
Sana Klinikum Offenbach
2015-2024
Universität Hamburg
2006-2023
University Medical Center Hamburg-Eppendorf
2005-2023
Krebsgesellschaft Nordrhein-Westfalen
2020-2021
Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage completion chemotherapy.
Purpose The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. Methods Tumor at surgery association with long-term outcome 6,377 patients primary receiving neoadjuvant anthracycline-taxane–based chemotherapy seven randomized trials were analyzed. Results Disease-free (DFS) was significantly superior no invasive situ residuals or nodes (n = 955) compared residual ductal carcinoma only 309), but...
Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy a worse prognosis than those no cancer. Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent (DM1), maytansine derivative microtubule inhibitor, provides benefit in patients with metastatic that was previously treated HER2-targeted therapy.
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) immunologically relevant genes neoadjuvant GeparSixto trial. Patients Methods investigated effect adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response...
Most patients with advanced ovarian cancer develop recurrent disease. For those who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over without paclitaxel; however, many clinically relevant neurotoxicity, frequently resulting in treatment discontinuation. Thus, an alternative regimen significant neurotoxicity was evaluated by comparing gemcitabine plus carboplatin single-agent platinum-sensitive patients.Patients were randomly...
This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of combination pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared standard paclitaxel (CP) in patients platinum-sensitive relapsed/recurrent ovarian cancer (ROC).Patients histologically proven recurrence more than 6 months after first- or second-line platinum taxane-based therapies were randomly assigned by stratified blocks CD (carboplatin area under curve [AUC] 5 plus...
PURPOSE Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively investigated its given simultaneously with anthracycline-taxane-based neoadjuvant chemotherapy. PATIENTS AND METHODS Patients operable or locally advanced, HER2-positive tumors were treated preoperatively four cycles of epirubicin/cyclophosphamide followed by docetaxel without capecitabine (EC-T[X]) and trastuzumab 6 mg/kg...
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal receptor 2 (HER2)–negative metastatic breast cancer. We evaluated the efficacy, measured according to rate of pathological complete response (absence invasive and intraductal disease axillary lymph nodes), safety adding bevacizumab neoadjuvant chemotherapy early-stage
Purpose Dose-dense and sequential administration of cytotoxic drugs are current approaches to improve outcomes in patients with early-stage breast cancer. Methods This phase III study investigated 913 women untreated operable cancer (T2-3, N0-2, M0) randomly assigned receive either doxorubicin 50 mg/m 2 plus docetaxel 75 every 14 days for four cycles filgrastim support (ADOC), or 60 cyclophosphamide 600 21 followed by 100 each (AC-DOC). The primary end point was the incidence pathologic...
We investigated disease-free survival (DFS) and overall (OS) after response-guided neoadjuvant chemotherapy in patients with early breast cancer.We treated 2,072 two cycles of docetaxel, doxorubicin, cyclophosphamide (TAC) randomly assigned responders to four (n = 704) or six 686) additional TAC cycles, nonresponders 321) vinorelbine capecitabine (NX; n 301) before surgery.DFS was longer receiving × 8 than those 6 (hazard ratio [HR], 0.78; 95% CI, 0.62 0.97; P .026), TAC-NX (HR, 0.59; 0.49...
Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In Adjuvant and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed early were randomly assigned to 1 year of T, L, sequence (T→L), or combination (L+T). The primary end point was disease-free survival...
<h3>Importance</h3> The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether<i>BRCA1</i>and<i>BRCA2</i>germline mutation status affects treatment outcome remains elusive. <h3>Objective</h3> To determine whether<i>BRCA1</i>and<i>BRCA2</i>germline therapy TNBC. <h3>Design, Setting,...